Regeneron breaks into neurology with FDA nod in crowded myasthenia gravis

Regeneron
While not a huge surprise, Livsayis’ green light is nevertheless “strategically important” for Regeneron as both its first small interfering RNA nod and the first for the New York drugmaker’s foray into neurology, Citi analysts wrote this week. (Photo by Lori Van Buren/Albany Times Union via Getty Images))

Underscoring how crowded the U.S. market for generalized myasthenia gravis (gMG) has become, the FDA on Wednesday approved the second targeted therapy for the neuromuscular disease this week, with the latest honor going to Regeneron and its Alnylam-licensed siRNA drug cemdisiran. 

Now christened Livsayis to treat adults with the most common form of gMG, Regeneron’s medicine wades into a bustling myasthenia gravis market of similarly classed C5 inhibitors like AstraZeneca’s Ultomiris and UCB’s Zylbrysq, plus FcRn-targeting drugs like UCB’s Rystiggo, Johnson & Johnson’s Imaavy and argenx’s prolific Vyvgart franchise. 

Livsayis is also the second new C5-directed therapy to enter the gMG fray since Monday, when the FDA gave the go-ahead to AstraZeneca’s gefurulimab, now approved under the brand name Klygefa in both the U.S. and EU. 

Both Regeneron’s and AstraZeneca’s new medicines are approved in patients who are anti-acetylcholine receptor (AChR) antibody-positive, making up the predominant form of gMG, although Livsayis holds the distinction of being the first siRNA therapy for the condition designed to silence the gene that makes C5 in the liver.

While the approval was “expected” and the competition ahead is likely to be fierce, Livsayis’ green light nevertheless marks a big win and stands out as “strategically important” for Regeneron as both its first small interfering RNA nod and the first for the New York drugmaker’s foray into neurology, Citi analysts wrote this week. 

Meanwhile, with so many targeted gMG therapies having crossed the commercial threshold, manufacturers are increasingly turning to differences in dosing routes and leveraging convenience pitches to set their medicines apart. 

Livsayis will be no different, with Regeneron emphasizing in its approval announcement Wednesday that its drug now stands as the only U.S. gMG treatment that can be given subcutaneously just four times a year. 

Still, the particulars of how patients will receive Livsayis could be a challenge in and of itself, the Citi team said, cautioning that the fact the drug must be administered by a healthcare provider “limits convenience.” 

To hit the higher end of the more than $1 billion in consensus 2032 sales estimates for the drug would require a mix of strong uptake, an eventual self-administration expansion and label growth beyond myasthenia gravis, the Citi team proposed. 

“We suspect initial use will be strongest among patients seeking more consistent disease control or lower treatment burden than more frequently administered complement inhibitors and neonatal Fc receptor therapies,” the analysts added. 

Dosing will also be a key component in AstraZeneca’s Klygefa pitch, with the drug cleared for self-administration at a patient’s home via a weekly autoinjector. 

As for the data underpinning Livsayis, Regeneron’s late-stage Nimble study tied its medicine to a 2.3-point placebo-adjusted improvement on the Myasthenia Gravis-Activities of Daily Living (MG-ADL) metric of gMG symptoms at 24 weeks.

Ahead of the company’s initial readout last summer, Regeneron’s SVP for investor relations and strategic analysis, Ryan Crowe, remarked at a TD Cowen event that “anything in the 2s ... would be a great result” when it came to the gMG readout. 

Regeneron’s study also posted promising signals around the early onset of benefit with Livsayis, which started helping patients chart improvements as early as two weeks into treatment, which the company said “deepened over time.” Further, the trial did not point to any waning efficacy of Regeneron’s drug through the 24-week treatment period. 

Livsayis will carry a boxed warning for serious meningococcal infections, plus warnings and precautions for other serious infections. 

This safety tag is largely consistent with other complement C5 inhibitor drugs “and should therefore be familiar to neuromuscular specialists,” the Citi team wrote Thursday. The drug will be made available via a Risk Evaluation and Mitigation Strategy (REMS), also in line with other medicines in its class.

“Livsayis is Regeneron’s first approved medicine in neurology, and an important new option for people living with generalized myasthenia gravis who need effective disease control without a heavy treatment burden,” George Yancopoulos, M.D., Ph.D., Regneron’s chief scientific officer, said in a statement. 

 “As Regeneron’s first approved siRNA therapy,” he continued, “this approval marks a meaningful step forward for our neuroscience pipeline as we relentlessly pursue bold, new approaches to transform care for people living with serious neurological diseases.”

Regeneron got its hands on Livsayis under a modification to its ongoing collaboration with RNA specialist Alnylam in 2024, handing its partner $10 million upfront with the promise of more potential milestone payments to come, including in the case of a monotherapy approval. 

As part of that Accord, Alnylam announced Thursday that the FDA nod has triggered a $25 million payment. The company is also eligible for tiered, double-digit royalties of up to 15% on future global sales of Livsayis. 

The approval, steered across the finish line by Regeneron, marks the seventh for an Alnylam-born RNAi therapeutic, the company pointed out.